Xenetic Biosciences, Inc. 4/A
4/A · Xenetic Biosciences, Inc. · Filed Jun 15, 2017
Insider Transaction Report
Form 4/AAmended
DEPTULA-HICKS DARLENE M
Director
Transactions
- Award
Stock Option
2016-12-20+10,000→ 20,000 totalExercise: $3.50From: 2017-06-20Exp: 2026-12-20→ Common Stock (10,000 underlying) - Award
Stock Option
2016-12-20+10,000→ 30,000 totalExercise: $3.50From: 2017-09-20Exp: 2026-12-20→ Common Stock (10,000 underlying) - Award
Stock Option
2016-12-20+10,000→ 40,000 totalExercise: $3.50From: 2017-12-20Exp: 2026-12-20→ Common Stock (10,000 underlying) - Award
Stock Option
2016-12-20+10,000→ 10,000 totalExercise: $3.50From: 2017-03-20Exp: 2026-12-20→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months.
- [F2]On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that she beneficially owned an aggregate of 61,416 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction.